Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions

Cancer patients have increased risk of severe cutaneous adverse reactions, without reliable biomarkers to identify predisposition for associated morbidity and mortality. In hospitalized cancer patients with morbilliform rash, elafin, IL-6, TNF-α were associated with mortality. IL-6, IL-10 were associated with drug-related systemic involvement. These biomarkers may guide future therapeutic research.